CAITLIN CUNNINGHAM: Open Payments
NPI 1730531187 · ARLINGTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,017 in 39 payments from 16 companies in 2025. Trend: 2023 $786 · 2024 $1,576 · 2025 $1,017
Food & beverage: $1,017
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $176 |
| Otsuka America Pharmaceutical, Inc. | 4 | $156 |
| Gilead Sciences, Inc. | 5 | $124 |
| Lundbeck LLC | 4 | $98 |
| Lilly USA, LLC | 4 | $97 |
| Bausch Health US, LLC | 4 | $81 |
| Astellas Pharma US Inc | 2 | $57 |
| PFIZER INC. | 3 | $56 |
| ABBVIE INC. | 2 | $31 |
| Novo Nordisk Inc | 1 | $28 |
Products named: REXULTI, AIRSUPRA, MOUNJARO, APLENZIN, Veozah, NURTEC ODT, Wegovy, BREZTRI.
Industry payments across VA — which companies pay providers there.
